Last reviewed: June 9, 2026 Last updated: June 9, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
She is dedicated to improving care for cardiometabolic conditions through accessible, affordable solutions for underserved communities
As weight loss medications remain a growing trend, salon professionals must stay informed about their broader effects on hair health
Dual GLP-1/glucagon agonists such as survodutide have demonstrated substantial hepatic fat reduction and MASH improvement, though tolerability optimization may be needed
Endogenous insulin is found in breastmilk in low levels
When people stay committed to Semaglutide GLP-1 for a year or more, they can experience a significant weight loss of up to 15 percent of their starting weight